+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gilead Sciences Inc - logo

Founded in 1987 Gilead Sciences is a biopharmaceutical company focused on developing innovative treatments for life threatening illnesses. Their areas of research include HIV/AIDs, Liver Diseases, Hematology, Oncology, Cardiovascular and Respiratory disease. Gilead Sciences is based in California, USA and their product portfolio consists of well-known treatments like Atripla, Sovaldi, Zydelig, Viread and many more.

2022 Leading Pharmaceutical Companies Capabilities, Goals and Strategies - Product Thumbnail Image

2022 Leading Pharmaceutical Companies Capabilities, Goals and Strategies

  • Report
  • April 2022
  • Global
From
Clinical Trials Sector Scorecard - Thematic Research - Product Thumbnail Image

Clinical Trials Sector Scorecard - Thematic Research

  • Report
  • October 2021
  • 24 Pages
  • Global
From
2021 What's Ahead for the Pharmaceutical Industry? - Emerging Opportunities and Growth Strategies for Suppliers - Product Thumbnail Image

2021 What's Ahead for the Pharmaceutical Industry? - Emerging Opportunities and Growth Strategies for Suppliers

  • Report
  • October 2021
  • Global
From
LAMEA Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application, By Technology, By Country and Growth Forecast, 2022 - 2028 - Product Thumbnail Image

LAMEA Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application, By Technology, By Country and Growth Forecast, 2022 - 2028

  • Report
  • May 2022
  • 91 Pages
  • Middle East, Africa
From
Asia Pacific Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application, By Technology, By Country and Growth Forecast, 2022 - 2028 - Product Thumbnail Image

Asia Pacific Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application, By Technology, By Country and Growth Forecast, 2022 - 2028

  • Report
  • May 2022
  • 93 Pages
  • Asia Pacific
From
Europe Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application, By Technology, By Country and Growth Forecast, 2022 - 2028 - Product Thumbnail Image

Europe Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application, By Technology, By Country and Growth Forecast, 2022 - 2028

  • Report
  • May 2022
  • 91 Pages
  • Europe
From
North America Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application, By Technology, By Country and Growth Forecast, 2022 - 2028 - Product Thumbnail Image

North America Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application, By Technology, By Country and Growth Forecast, 2022 - 2028

  • Report
  • May 2022
  • 84 Pages
  • North America
From
Ischemia Reperfusion Injury - Pipeline Review, H2 2020 - Product Thumbnail Image

Ischemia Reperfusion Injury - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 197 Pages
  • Global
From
Pharmaceutical Industry in the United States 2022 - Product Thumbnail Image

Pharmaceutical Industry in the United States 2022

  • Report
  • September 2022
  • 150 Pages
  • United States
From
Bone Marrow Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Bone Marrow Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 555 Pages
  • Global
From
Gastric Cancer - Pipeline Review, H2 2020 - Product Thumbnail Image

Gastric Cancer - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 2657 Pages
  • Global
From
PharmSource: Contract Manufacturing of Novel In-Licensed Drugs - 2020 Edition - Product Thumbnail Image

PharmSource: Contract Manufacturing of Novel In-Licensed Drugs - 2020 Edition

  • Report
  • February 2020
  • 24 Pages
  • Global
From
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drugs in Development, 2021 - Product Thumbnail Image

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drugs in Development, 2021

  • Report
  • November 2021
  • 126 Pages
  • Global
From
Pharmaceutical Drug Development Sector Scorecard, Q2 2022 Update - Thematic Research - Product Thumbnail Image

Pharmaceutical Drug Development Sector Scorecard, Q2 2022 Update - Thematic Research

  • Report
  • June 2022
  • 16 Pages
  • Global
From
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022 - Product Thumbnail Image

Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022

  • Report
  • December 2022
  • 43 Pages
  • Global
From
Drug Development Sector Scorecard - Q4 2021 Update - Thematic Research - Product Thumbnail Image

Drug Development Sector Scorecard - Q4 2021 Update - Thematic Research

  • Report
  • December 2021
  • 16 Pages
  • Global
From
Social Responsibility Trends in Healthcare - Thematic Intelligence - Product Thumbnail Image

Social Responsibility Trends in Healthcare - Thematic Intelligence

  • Report
  • March 2023
  • 54 Pages
  • Global
From
Corporate Governance Trends in Healthcare - Thematic Intelligence - Product Thumbnail Image

Corporate Governance Trends in Healthcare - Thematic Intelligence

  • Report
  • February 2023
  • 55 Pages
  • Global
From
Environmental Trends in Healthcare - Thematic Intelligence - Product Thumbnail Image

Environmental Trends in Healthcare - Thematic Intelligence

  • Report
  • January 2023
  • 57 Pages
  • Global
From
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Global Drug Sales Forecast - Q4, 2021 - Product Thumbnail Image

Coronavirus Disease 2019 (COVID-19) Analyst Consensus Global Drug Sales Forecast - Q4, 2021

  • Report
  • December 2021
  • 38 Pages
  • Global
From
Loading Indicator